# Esperion Therapeutics (ESPR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ESPR
## Company Profile
- Ticker: ESPR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 3.18 USD
- Market cap: 808336297.88 USD
- Last updated: 2026-07-10
## Business Overview
### Oral Cardiometabolic Medicines
Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase.
### Bempedoic Acid Franchise
NEXLETOL and NEXLIZET are once-daily, non-statin LDL-cholesterol-lowering medicines based on bempedoic acid. Esperion commercializes the products in the United States and works with partners across more than 40 countries.
### Enbumyst Expansion
Esperion has agreed to acquire Corstasis Therapeutics and Enbumyst, an approved bumetanide nasal spray. The product would add a differentiated diuretic to its cardiovascular commercial portfolio.
### Combination Development
The company is developing oral triple-combination regimens intended to deliver larger LDL-C reductions through complementary mechanisms. These products are designed to compete with other intensive lipid-lowering options while retaining oral administration.
### Rare-Disease Pipeline
ESP-2001 is a wholly owned program for primary sclerosing cholangitis, a rare liver disease without approved treatment. Esperion is also applying its ACLY expertise to additional next-generation programs.
## Why The Stock Is Moving

Current closing-price context is not available for ESPR.

## Future Catalysts

- Canadian approval decision for NEXLIZET expected in 2026.
- Australian decisions on NEXLETOL and NEXLIZET expected in the fourth quarter of 2026.
- Completion of clinical requirements and planned commercialization of oral triple-combination products in 2027.

## Recent News
- 2026-05-26 12:00 EST — [Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study-at-the-european-atherosclerosis-society-congress-2026) — Source: Esperion Therapeutics
- 2026-05-14 20:30 EST — [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Esperion Therapeutics
- 2026-05-13 12:00 EST — [Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-announces-two-new-analyses-supporting-bempedoic-acid-to-reduce-ldl-c-levels-to-be-presented-at-the-european-atherosclerosis-society-eas-congress-2026) — Source: Esperion Therapeutics
- 2026-05-01 11:00 EST — [Esperion to be Acquired by ARCHIMED](https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed) — Source: Esperion Therapeutics
- 2026-04-23 12:00 EST — [Esperion to Report First Quarter 2026 Financial Results on May 7](https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7) — Source: Esperion Therapeutics